Snowball logo
logo
1FG_logo

FibroGen Inc

€5.5425€0.00  (0%)
Estimate
EPS
-25.97
Beta
0.819
About the company
Ticker
1FG
ISIN
US31572Q8087
Country
United States of America
Sector (GICS)
Healthcare
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Frequently asked questions

What sector does FibroGen Inc (1FG) operate in?

FibroGen Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is FibroGen Inc (1FG) current stock price?

As of the latest data, FibroGen Inc stock price is €5.54, with a previous close of €5.54.

What is FibroGen Inc (1FG) current market capitalization?

FibroGen Inc market cap is approximately 22.40 million.

What is FibroGen Inc (1FG) Earnings Per Share (EPS)?

The trailing EPS is -€25.97.

Does FibroGen Inc (1FG) pay dividends?

No. FibroGen Inc does not pay a dividend.

What is FibroGen Inc (1FG) beta (volatility) score?

FibroGen Inc has a beta of 0.819, meaning its volatility is roughly in line with the market.